104890-73-5

Basic information

• Product Name: 1-(4-CHLOROPHENYL)-3-(2,6-DICHLOROPHENYL)PROP-2-EN-1-ONE
• Synonyms: 1-(4-CHLOROPHENYL)-3-(2,6-DICHLOROPHENYL)PROP-2-EN-1-ONE;2,4',6-TRICHLOROCHALCONE
• CAS NO: 104890-73-5
• Molecular Formula: C₁₅H₉Cl₃O
• Molecular Weight: 311.59
• Mol File: 104890-73-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 445.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.380±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1-(4-CHLOROPHENYL)-3-(2,6-DICHLOROPHENYL)PROP-2-EN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-CHLOROPHENYL)-3-(2,6-DICHLOROPHENYL)PROP-2-EN-1-ONE(104890-73-5)
• EPA Substance Registry System: 1-(4-CHLOROPHENYL)-3-(2,6-DICHLOROPHENYL)PROP-2-EN-1-ONE(104890-73-5)

Safety Data

• Hazardous Substances Data: 104890-73-5(Hazardous Substances Data)

Usage

Appearance

Bright yellow color

Taste

Characteristic taste

Natural Source

Found in the rhizome of the turmeric plant

Traditional Use

Used for centuries in traditional medicine

Health Benefits

Potential anti-inflammatory, antioxidant, and anticancer properties

Additional Effects

Being investigated for neuroprotective and antidepressant effects

Industrial Applications

Used as a food coloring and flavoring agent

Other Uses

Applications in the pharmaceutical and cosmetic industries

Upstream product

• 99-91-2 para-chloroacetophenone 
• 83-38-5 2,6-dichlorobenzaldehyde 

Downstream Products

• 847246-73-5 5-(4-chlorophenyl)-7-(2,6-dichlorophenyl)-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine 

Relevant articles and documents

Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion

The high levels of hepatitis B virus (HBV) surface antigen (HBsAg)-bearing subviral particles in the serum of chronically infected individuals play an important role in suppressing HBV-specific immune response and are only mildly affected by the current small molecule therapies. Thus, a therapy that specifically reduces HBsAg serum levels could be used in combination therapy with nucleos(t)ide drugs or permit therapeutic vaccination for the treatment of HBV infection. Herein, we report the design, synthesis, and evaluation of novel triazolo-pyrimidine inhibitors (1, 3, and 4) of HBsAg cellular secretion, with activity against drug-resistant HBV variants. Extensive SAR led to substantial improvements in the EC50 of the parent compound, 5 (HBF-0259), with the best being 3c, with EC50 = 1.4 ± 0.4 μM, SI ≥ 36. The lead candidates, both 1a (PBHBV-001) and 3c (PBHBV-2-15), were well-tolerated in both normal and HBV-transgenic mice and exhibited acceptable pharmacokinetics and bioavailability in Sprague-Dawley rats.